DAFTAR PUSTAKA
1. MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J. 2007(83): 690-7.
2. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev. Dermatol. 2006(1): 63-75.
3. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanism in psoriasis. Clin Exp Immunol. 2004(135):1-8.
4. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin.2008(22):349-69.
5. Almakhzangy I, Gaballa A. Serum level of IL-17, IL-22, IFN-γ in patients with psoriasis. Egyptian Dermatology Online Journal 2009;5(1): 1-7. 6. Ragab MH,Maksoud NA, Roaiah M.Biochemical significance of pro
inflammatory cytokines in psoriasis vulgaris among Egyptian patients. Journal of American Science.2010;6(10):423-8.
7. Tesmer LA,Lundy SK,Sarkar S,Fox DA. Th17 cells in human disease. Immunological reviews.2008 (223): 87-113.
8. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis:key roles for IL-23, Il-17A and TGF-β1. Expert Rev Dermatol.2007 (1):69-71.
9. Ortega C,Fernandez S, Carillo JM, Romero P, Molina IJ, Moreno IC, Santamaria M. IL-17 producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. Journal of Leukocyte Biology. 2009(86):435-42.
10. Griffiths CEM., Barker JNW.Pathogenesis and clinical features of psoriasis, Lancet, 2007(370):263-71.
11. Arican O, Aral M, Sasmaz S, Gragil P. Serum levels of TNF-α, IFN-γ, IL -6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators of inflammation.2005(5):273-9.
12. Gudjonsson JE, Elder JT. Psoriasis dalam Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editor. Fitzpatrick’s dermatology in general medicine. Edisi-8. New York: McGrawHill Incoorporate; 2012:197-231.
13. Traub M, Marshall K. Psoriasis-pathophysiology, conventional, and alternative approaches to treatment. Alternative Medicine Review 2007(12):319-30.
14. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft D. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. The society for investigative Dermatology. 2013 (133) : 377 -83.
15. Sanchez APG. Immunopathogenesis of psoriasis. An Bras Dermatol. 2010( 85):747-9.
16. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007( 299):359-66.
17. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J.Am.Acad.Dermatol.2005(53):94-100.
18. Nestle FO, Kaplan DH, Barker,J.Psoriasis.N Engl J Med.2009(361):496-509.
19. Coimbra S, Oliveira H, Figueiredo A, Rocha-Pereira P, Santos-silva A. Psoriasis: Epidemiology, clinical and histological features, triggering factors, assessment of severity and psychosocial aspects. IntechopenJ. 2004 (3):69-82.
20. Smith CH, Barker JNWN. Psoriasis and its management. BMJ.2006 (333): 380-4.
21. Miossec P, Korn T, Kuchroo V. Interleukin-17 and Type 17 helper T cells. N Engl J Med 2009(361): 888-98.
22. Wynn TA. Th17: a giant step from Th1 and Th2. Nature Immunology. 2005(6):1069-70.
23. Romagnani S. Human Th17 cells. Arthritis Research&therapy 2008(10):206.
24. Mesquita D, Cruvinel WM, Camara NOS, Kallas EG, Andrade LEC. Autoimmune diseases in the Th7 era. Braz J Med Biol Res.2009(42):476-86.
25. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature.2006 (44 ): 235-8. 26. Chung Y, Yang X, Chang SH. Expression and regulation of IL-22 in the
IL-17 producing CD4+T lymphocytes. Cell Research 2006(16): 902-7. 27. Langrish CL, Blumenschein WM, Mattson J, Basham B, Sedgwick JD,
McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. JEM. 2004(201): 233-40.
28. Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation, autoimmunity and therapy. Review. J Periodontol. 2007(78): 1083-90. 29. Witowski J, Ksiazek K, Jurres A. Interleukin-17: a mediator of
inflammatory responses. CMLS Cell Mol Life Sci.2004(61):567-79.
30. Gaffen SL, An overview of IL-17 function and signaling. Cytokine 2008(3): 402-7.
31. Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. International Journal of Inflammation. 2012(212):1-7.
32. Manel N, Unutmaz D, Littman DR. The differentiation of human Th17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nature Immunology.2008(9): 641-7.
33. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007(19):362-71.
34. Louten J, Boniface K, Malefyt RW. Development and function of Th17 cells in health and disease. J Allergy Clin Ummunol. 2009:1004-9.
35. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LS, Haider AS, Boman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete ppulations of Th1 and Th17 T cells. Journal of investigative Dermatology. 2008(128):1207-11.
36. Meglio PD, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. Biology reports. 2010 (2): 1-5.
37. Meier M., Sheth PB. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol. Basel, Karger. 2009 (38):1-20.
38. Luo q., Zhang X., Luo Y., Lin L., Li J., Zhang S., Liu Y. Increased expression of Th17 cytokines in patients with psoriasis. African Journal of Biotechnology. 2012 (11):3413-5.
39. Sinniah B, Devi S, Prashant D. Epidemiology of Psoriasis in Malaysia: A Hospital Based Study.Med J Malaysia.2010 (2):112-14.
40. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. Journal of autoimmunity. 2010 (34):314-21.
41. Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis pathogenesis and targeted therapy. Review. Psoriasis Targets and Therapy. 2013(3):1-10.
